Skip to main content
SpringerLink
Log in

A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography

  • Pharmacologic Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The anthracycline analog 4′-deoxydoxorubicin (4′ -deoxyDX) is a clinically promising antineoplastic agent due to its high potency, broad spectrum of activity, and decreased cardiotoxicity relative to DX. To assess its physicochemical properties and disposition kinetics, we have developed a rapid, sensitive, and precise HPLC assay for the simultaneous analysis of 4′ -deoxyDX and its potential metabolites in biological samples. The assay has a detection limit of 5 ng/ml with an average recovery of 95 ± 5%. Precision of the assay is less than 7%. Using this assay we have measured the concentrations of 4′-deoxyDX in patient plasma and urine after an intravenous injection of 4′-deoxyDX. A major metabolite, which co-eluted chromatographically with 4′-deoxydoxorubicinol, was observed in both plasma and urine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arcamone F, Bernardi L, Patelli B, et al.: Synthesis and antitumor activity of new daunorubicin and adriamycin analogs. Experimenta 34(10):1255–1257, 1978

    Google Scholar 

  2. Cagnasso M (ed): Summary of Preclinical Studies of IMI-58(4′-deoxydoxorubicin) up to April, 1981. (Farmitalia CarloErba)3. Salmon SE, Lui R, Casazza AM: Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:103–109, 1981

    Google Scholar 

  3. Salmon SE, Lui R, Casazza AM: Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:103–109, 1981

    Google Scholar 

  4. Ferrari L, Rossi A, Brambilla C, Villani F, Bonfante V, Bonadonna G: Phase I study with 4′-deoxydoxorubicin (deoxyDX). (Abstract). Proc Am Assoc Cancer Res 24:644, 1983

    Google Scholar 

  5. Israel M, Pegg WJ, Wilkinson PM, Garnick MB: Liquid Chromatographic analysis of adriamycin and metabolites in biological fluids. J Liq Chromatog 1:795–809, 1978

    Google Scholar 

  6. Robert J: Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatog 3:1561–1572, 1980

    Google Scholar 

  7. Andrews PA, Brenner DE, Chow FTE, Kubo H, Bachu NR. Facile and definitive determination of human adriamycin and daunorubicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 8:152–156, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Department of medicine, University of Arizona, Tucson, Arizona, USA

    Yei-Mei Peng Ph.D., David S. Alberts & Sydney E. Salmon

  2. Department of Pharmacology, University of Arizona, Tucson, Arizona, USA

    David S. Alberts & Thomas P. Davis

  3. Cancer Center, University of Arizona, Tucson, Arizona, USA

    Yei-Mei Peng Ph.D., David S. Alberts, Sydney E. Salmon & Thomas P. Davis

Authors
  1. Yei-Mei Peng Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David S. Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sydney E. Salmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas P. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peng, YM., Alberts, D.S., Salmon, S.E. et al. A method for the simultaneous measurement of the new anthracycline derivative 4′ -deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Invest New Drugs 2, 277–280 (1984). https://doi.org/10.1007/BF00175377

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175377

Keywords

Search

Navigation